No Data
No Data
Piper Sandler Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $30
Piper Sandler analyst Yasmeen Rahimi maintains $Benitec Biopharma(BNTC.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 38.9%
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Benitec Biopharma (BNTC)
Benitec Biopharma Reports Promising Interim Study Results
Express News | Benitec Biopharma Inc - Remain on Track to Report Additional Interim Clinical Study Results on Multiple Patients in Q1 of Calendar 2025
Express News | Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First Opmd Subject Treated With Low-Dose Bb-301 in Phase 1B/2a Study
JMP Securities Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Silvan Tuerkcan maintains $Benitec Biopharma(BNTC.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 35.
No Data